Kenneth Luu

Kenneth Luu joined AnaptysBio in January of 2021 and leads the clinical pharmacology, bioanalytical, and toxicology functions. Ken has more than 20 years of nonclinical and clinical drug development experience, particularly in the areas of DMPK, clinical pharmacology, and pharmacometrics. Prior to joining AnaptysBio, Ken held various positions at Pfizer, Allergan, and Ionis Pharmaceuticals and supported a wide range of drug modalities including small molecules, monoclonal antibodies, antibody-drug conjugates, and oligonucleotides. He has worked in teams that contributed to the approvals of products such as Besponza™, Spinraza®, and Durysta™. Ken received his Ph.D. in Pharmaceutical Sciences at the University of the Pacific and his B.S. in Biological Sciences at the University of California, Irvine.